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Background: Indices of left ventricular (LV) structure and geometry represent useful
intermediate phenotypes related to LV hypertrophy (LVH), a predictor of cardiovascular
(CV) disease (CVD) outcomes.
Methods and Results: We conducted an exome-wide association study of LV mass
(LVM) adjusted to height2.7, LV internal diastolic dimension (LVIDD), and relative wall
thickness (RWT) among 1,364 participants of African ancestry (AAs) in the Hypertension
Genetic Epidemiology Network (HyperGEN). Both single-variant and gene-based sequence
kernel association tests were performed to examine whether common and rare coding
variants contribute to variation in echocardiographic traits in AAs. We then used a datadriven procedure to prioritize and select genes for functional validation using a human
induced pluripotent stem cell cardiomyocyte (hiPSC-CM) model. Three genes [myosin
VIIA and Rab interacting protein (MYRIP), trafficking protein particle complex 11
(TRAPPC11), and solute carrier family 27 member 6 (SLC27A6)] were prioritized based
on statistical significance, variant functional annotations, gene expression in the hiPSC-CM
model, and prior biological evidence and were subsequently knocked down in the
hiPSC-CM model. Expression profiling of hypertrophic gene markers in the knockdowns
suggested a decrease in hypertrophic expression profiles. MYRIP knockdowns showed
a significant decrease in atrial natriuretic factor (NPPA) and brain natriuretic peptide (NPPB)
expression. Knockdowns of the heart long chain fatty acid (FA) transporter SLC27A6
resulted in downregulated caveolin 3 (CAV3) expression, which has been linked to
1
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hypertrophic phenotypes in animal models. Finally, TRAPPC11 knockdown was linked to
deficient calcium handling.
Conclusions: The three genes are biologically plausible candidates that provide new
insight to hypertrophic pathways.
Keywords: exome sequencing, left ventricular hypertrophy, echocardiograph, cardiomyocyte model, hypertension,
African-American

INTRODUCTION

MATERIALS AND METHODS

Changes in left ventricular (LV) structure and geometry may
evolve with myocardial injury or pressure overload and can lead
to chamber dilation and/or hypertrophy (Gaasch and Zile, 2011).
Echocardiography can identify such changes, while providing
useful intermediate phenotypes predictive of cardiovascular (CV)
disease (CVD) outcomes (Vasan et al., 2009). Left ventricular
mass (LVM), used clinically to define left ventricular hypertrophy
(LVH), is an independent predictor of premature mortality across
all genders, races, and ages (Casale et al., 1986; Levy et al., 1990;
Gaasch and Zile, 2011). Additionally, increased LV wall thickness
predicts CVD events (Vasan et al., 1997b), and LV dilation predicts
heart failure (Vasan et al., 1997a; Gardin et al., 2006).
It is widely accepted that genetic factors influence LVM
and other structural cardiac phenotypes. Heritability estimates
for LVM (Sharma et al., 2006), LV internal diastolic dimension
(LVIDD), and LV relative wall thickness (RWT) range between
25 and 50% (Fox et al., 2010; Jin et al., 2011). Linkage (Arnett
et al., 2009a; Fox et al., 2010), candidate gene association
(Arnett et al., 2009a; Lynch et al., 2012), and genome-wide
association studies (Arnett et al., 2009b, 2011; Vasan et al.,
2009) have reported loci suggestively or significantly associated
with structural and functional echocardiographic traits.
Similar to the increased risk of hypertension and other
CVDs, individuals of African ancestry (hereafter AAs) have
greater average LV structural dimensions and other LV structural
differences relative to individuals of European ancestry. LVH
contributes more to the risk of CV mortality in AAs than it
does in other ancestry groups (Havranek et al., 2008). Also,
AAs have a higher prevalence of concentric LVH characterized
by an increased LVM and RWT (hypertrophic LV growth
without overall chamber enlargement), which has a poorer
prognosis and is usually the result of increased systolic pressure
(Gaasch and Zile, 2011; Ahmad et al., 2017). Overall, the
extent to which genetic factors influence differences in LV
phenotypes and the unique etiology of subclinical LVH in
hypertension-prone AAs remain poorly understood.
We conducted a whole-exome association study of structural
echocardiographic traits, including LVM adjusted to height2.7
(LVM/Ht2.7), LVIDD, and RWT among AAs from the Hypertension
Genetic Epidemiology Network (HyperGEN; Williams et al.,
2000). Both single-variant and gene-based association tests were
performed to examine the association between common and
rare coding variants and echocardiographic traits in AAs. We sought
functional validation of the association findings using a human
induced pluripotent stem cell cardiomyocyte (hiPSC-CM) model.

Study Population

Frontiers in Genetics | www.frontiersin.org

Hypertension Genetic Epidemiology Network is one of the four
networks in the National Heart, Lung and Blood Institute’s Family
Blood Pressure Program, which aimed to identify genetic
contributors to hypertension. As part of HyperGEN, hypertensive
AA sibships were recruited from the community-at-large in
Birmingham, AL, and population-based cohorts in Forsyth County,
NC, from 1995 to 2000. Sibling pairs with onset of hypertension
before age 60 years were recruited in the first phase. In a second
phase, the study was extended to include other siblings as well
as offspring of the hypertensive probands who were not being
treated for hypertension. This study included 1,434 self-reported
AA participants with relevant echocardiographic measurements
and exome sequence data. The study was approved by the
Institutional Review Boards of the participating organizations.
All HyperGEN participants provided informed consent for use
of samples and data for subsequent analyses.

Echocardiographic Data

Left ventricular traits were assessed by two-dimensional-guided
M-mode echocardiography at the Birmingham, AL, and Forsyth
County, NC field centers following a standardized imaging and
reading protocol. All instruments were calibrated against a
standard phantom at installation and were validated regularly
(Tang et al., 2002). Certificated sonographers from each center
were trained at the echocardiography reading center at New York
Hospital-Weill Cornell Medical Center where measurements were
computerized, calibrated, and quantified using a review station
with digitizing tablet and monitor overlay (Arnett et al., 2009a).
The study assessed LV structural phenotypes including LVM,
LVIDD, and RWT. LVM was calculated with the following
formula: LVM = 0.8 × 1.04 × [(IVS + LVIDD + PWT)3 −
LVIDD3] + 0.6 g, in which IVS is the interventricular septum
thickness and PWT is the posterior wall thickness at end-diastole
(in cm). IVS, PWT, and LVIDD were measured according to
the American Society of Echocardiography recommendations
(Devereux et al., 1984a). LVM was further indexed to height
in meters2.7. RWT was calculated as twice the PWT divided
by the LVIDD (Devereux et al., 1984b).

Exome Sequence Data

Exome sequencing was performed at the University of Washington
(Auer et al., 2015). The processes of library construction, exome
capture, sequencing, and mapping were performed as previously

2
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described (Tennessen et al., 2012). Samples of DNA were quality
controlled by concentration estimation by PicoGreen® (Thermo
Fisher Scientific, Waltham, MA, United States). DNA samples
were prepared by subjecting genomic DNA to shearing followed
by ligation of sequencing adaptors. Exome capture for the
samples was performed using the Roche Nimblegen SeqCap®
EZ (Roche, Pleasanton, CA, United States) according the
manufacturer’s instructions. Paired-end sequencing (2 × 76 bp)
was performed using GAII® and HiSeq® (Illumina, San Diego,
CA, United States) sequencing instruments. For quality control
(QC) purposes prior to release of sequence data, samples
were initially converted from real-time base-calls to qseq.txt
files using Illumina’s standard base caller, Bustard, and aligned
to hg19 human reference using Burrows-Wheeler Aligner (Li
and Durbin, 2010). Duplicate removal and insertion-deletion
(INDEL) realignment were performed using the Genome
Analysis ToolKit (GATK®, Broad Institute, Cambridge, MA;
McKenna et al., 2010). After using GATK filters, samples
were required to reach at least 20x coverage over 70% of
the exome target. Prior to release of individual-level sequence
reads, sequence data were required to match known fingerprint
genotypes for their respective samples.

completion; (e) capture uniformity; (f) raw error rates; (g) Ti/Tv
ratio: typically 3.2 for known sites and 2.9 for novel sites
(Wang et al., 2015); (h) distribution of known and novel variants
relative to dbSNP (Ng et al., 2009); (i) fingerprint concordance
>99%; (j) homozygosity; (k) heterozygosity; and (l) sample
contamination validation. All QC metrics for both single-lane
and merged data were reviewed by a sequencing analyst to
identify data deviations from known or historical norms.

Variant Quality Control

To minimize false positives, only the following variants were
retained: (a) genotyping quality > 20; (b) depth of coverage
> 8; (c) bi-allelic variants (i.e., SNPs only); and (d) samplelevel genotype missing rate of < 10%. We included only autosomal
SNPs. The above SNP-filtering criteria reduced the SNP space
from 528,450 to 397,723, with 353,686 SNPs having a minor
allele frequency (MAF) < 5%, of which 134,548 (38%) SNPs
were singletons. The working set of 397,723 SNPs was further
annotated using ANNOVAR and variants with MAF < 5% were
classified into categories of replacement mutations [i.e., missense
(nonsynonymous) and loss-of-function (stop-gain and stop-loss)
mutations, see Supplementary Table S1]. Based on these
annotations, a total of 202,697 were deemed probable deleterious
and damaging variants: 199,104 missense mutations; 3,454 stopgain; and 139 stop-loss. ANNOVAR was used to capture
functional prediction scores and classifications.

Variant Calling Approach

All subjects were whole-exome sequenced at average mean read
depth was 25. GATK’s best practice for calling germline variants
is a multistep approach, which invokes the following GATK
modules: (a) HaplotypeCaller module to generate per-sample,
intermediate genomic variant call format (GVCF) files; (b)
ImportGenomicsDB module to consolidate sample-level GVCF
files; (c) GenotypeGVCF module to jointly call single-nucleotide
polymorphisms (SNPs) and INDELs; and (d) VariantRecalibrator
and ApplyRecalibration modules to retain high-quality variants
and calibrate them to balance sensitivity and specificity. This
multi-step approach produced a total of 642,878 variants across
the 1,434 samples, which were further reduced to 528,450 variants
with Variant Quality Score Log-Odds scores >0.99 derived from
GATK’s Variant Quality Score Recalibration.

Statistical Analysis

A total 1,364 participants of 1,382 had genetic and
echocardiographic data available for this analysis. Prior to
performing genetic association tests, echocardiographic traits
were transformed as needed to meet distributional assumptions
(natural log transform of LVM/Ht2.7, LVIDD, and RWT). To
address potential population stratification, we performed PC
analysis using EIGENSTRAT’s Smartpca module with variants
with MAF > 5%. The first 10 PCs were found to capture
ancestral variation and hence were used as covariates in the
downstream statistical analysis.
Genetic association was assessed at both the single-variant
level [with minor allele count (MAC) > 5] as well as the gene
level (no MAC filter) using RAREMETAL and
RAREMETALWORKER (RMW; Liu et al., 2014), which reports
results from gene-based tests including the Sequence Kernel
Association Test (SKAT-RMW) which adjusts for family
relationship. Since RMW does not include a function for joint
testing of rare and common variants and our hypothesis centered
around this combination of variants, we additionally implemented
SKAT (Wu et al., 2011) outside of the RMW framework, with
a focus on the rare/common SKAT function (SKAT-RC; IonitaLaza et al., 2013). Models were adjusted for age, sex, recruitment
center, and the top 10 PCs as fixed effects and kinship coefficients
for sample relatedness within families (SKAT-RMW output
only). In a sensitivity model, we additionally adjusted for body
mass index [BMI, weight (kg)/height2 (m2)] and in a second
sensitivity analysis we adjusted for hypertension status. The
Bonferroni-corrected significance thresholds for single variant

Sample Quality Control

To ensure retention of high-quality samples relevant to our
research study, 1,434 genomic samples were reduced to 1,382
through a quality-assurance pipeline that involved (a) removal
of duplicate or twin sib pairs; (b) removal of blood sample
mix-ups; and (c) removal of one non-AA sample through
estimation of genetic principal components (PCs).
Additional quality assessment metrics were evaluated to
retain high confidence samples and variants for downstream
statistical analysis. After aligning the generated paired-end read
sequences, the following QC steps were implemented: (a) total
reads: exome completion typically requires a minimum of 30 M
PE50 reads; (b) library complexity: the ratio of unique reads
to total reads mapped to target (DNA libraries exhibiting low
complexity are not cost-effective to finish); (c) capture efficiency:
the ratio of reads mapped to human vs. the reads mapped to
target; (d) coverage distribution: 90% at ≥8x required for
Frontiers in Genetics | www.frontiersin.org
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and gene-level tests were p < 2.5 × 10−7 (i.e., 0.05/202,697
variants) and p < 3.01 × 10−6 (i.e., 0.05/16,579 genes), respectively.
However, we used a gene-based test p < 1 × 10−4 and other
information to prioritize genes for cell model experiments (see
Gene Selection section below).

four criteria were supportive: (1) association (p < 0.05) with
more than one of the structural traits, (2) harboring a loss of
function variant, (3) previously linked to hypertrophy in the
literature, and/or (4) having a mix of rare and common variants
contributing to the gene-based statistic. To prioritize genes for
functional validation analysis using knockdown experiments,
we summed the count of each criteria for a total of seven
possible points and prioritized the gene selection by the total
count. This procedure resulted in four genes with a prioritization
score of 5. One of the four genes, prostaglandin E receptor 3
(PTGER3), was not practical for knockdown in our model due
to its role in cell signaling (i.e., PTGER3 is a prostaglandin
receptor and cardiomyocytes do not produce prostaglandins).

hiPSC-CM Models

hiPSC-CM Cell Lines and Hypertrophy Model

We utilized iCell® Cardiomyocytes (iCell-CMs) from hiPSCs
[Cellular Dynamics International (CDI), Madison, WI,
United States] to determine mRNA expression patterns; this
particular line was derived from the fibroblast of a Caucasian
female (<18 years old) using the retroviral transduction
reprogramming method (Cellular Dynamics, 2020). These
cardiomyocytes are a highly pure ventricular population having
functional properties similar to adult human cardiomyocytes
(Kattman et al., 2011; Ma et al., 2011). iCell-CMs were plated
at 2.0 × 104 cells/well in a 96-well plate pre-coated with
fibronectin (5 μg/ml). After 10 days of recovery in iCell
Maintenance Medium (CDI), the cells were cultured in William’s
E medium supplemented with Cocktail B (1:25) from the
Hepatocyte Maintenance Supplement Pack (Life Technologies
Gibco®, Thermo Fisher Scientific) for an additional 4 days.
After a total of 14 days of culture, cells were harvested
with Total RNA Purification 96-Well Kit (Norgen Biotek Corp,
Thorold, ON, Canada). Total RNA was extracted per
manufacturer’s recommendations, resuspended in nuclease-free
water, and quantified by UV spectrophotometry (NanoDrop 2000,
Thermo Fisher Scientific). Quality of total RNA was evaluated
using total RNA Pico chip analysis on Agilent 2,100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, United States).

Knockdown Experiments

Gene knockdown experiments were conducted in iCell-CMs using
commercially available small interfering (si) RNAs (Thermo Fisher
Scientific) targeting the identified candidate genes. hiPSC-CMs
were plated in 96-well dishes at an approximate density of 1.71 × 104
cells/well. Transfections were performed in triplicate using
Invitrogen’s Lipofectamine® RNAiMAX reagent (Thermo Fisher
Scientific) per manufacturer’s instructions. Each siRNA transfection
was conducted using two unique Ambion® siRNAs (Thermo
Fisher Scientific) per gene to ensure efficient gene knockdown.
Invitrogen’s Block-iT™ fluorescent control (Thermo Fisher Scientific)
was used as a positive control, with successful nuclear-localized
fluorescence. Two negative controls were run with no discernable
effect: (1) the transfection reagent without siRNAs and (2) Ambion®
Silencer™ Negative Control No. 3 siRNA (Thermo Fisher Scientific).
RNA extractions were performed with Norgen’s Total RNA
purification 96-well kit (Norgen Biotek Corp). The knockdown
efficiency was determined via real-time quantitative PCR (RT-qPCR)
using TaqMan™ (Roche) gene expression assays following the
manufacturer’s recommendations, normalizing to GAPDH, and
compared to the Silencer Negative Control No. 3.

Illumina Hiseq Sequencing

We analyzed gene expression for the gene prioritization and
selection analysis using RNA sequencing (RNA-seq). Paired-end
cDNA libraries were prepared from 500 ng of total RNA from
the iCell cardiomyocytes, using the TruSeq® RNA Sample
Preparation Kit (Illumina). External RNA Controls Consortium
(Baker et al., 2005) reference materials were added to each
RNA sample per manufacturer’s recommendations. Samples
were sequenced on the Illumina HiSeq instrument following
the manufacturer’s instructions. The samples were sequenced
to a depth of at least 40 million paired-end reads per sample.

Targeted Whole-Transcriptome Sequencing

Targeted whole-transcriptome RNA sequencing was performed
using the Ion AmpliSeq™ Transcriptome Human Gene Expression
Kit (Thermo Fisher Scientific) on total RNA extracted from the
iCell-CM knockdown experiments. Barcoded cDNA libraries
were generated from 10 ng of total RNA, following manufacturer’s
instructions. Quality of libraries was confirmed and quantification
was done using Agilent Bioanalyzer High Sensitivity DNA Kit
(Agilent Technologies). Sequencing was performed on the Ion
Torrent™ Ion Proton™ sequencing platform (Thermo Fisher
Scientific), using the Ion PI Hi-Q Sequencing 200 Kit. Three
biological replicates were run for each condition.

Gene Selection for hiPSC-CM Knockdown
Experiments

Since all gene-based statistical tests include assumptions that
may not perfectly fit the underlying genetic model, we prioritized
genes for functional follow-up with a combination of criteria
using a point-counting approach similar to that of previous
work in HyperGEN (Zhi et al., 2012). We required genes to
be: (1) associated with at least one structural trait (LVIDD,
RWT or LVM/Ht2.7 with p < 1.0 × 10−4); (2) previously associated
broadly with cardiovascular disease or metabolism in the literature;
and (3) expressed in the hiPSC-CM model (see Illumina HISeq
Sequencing section above) for a total of three points. The following
Frontiers in Genetics | www.frontiersin.org

Hypertrophic Gene Markers in siRNA Knockdown
Experiments

Genes previously linked to hypertrophy, as reflected by an
increase in LV wall thickness and/or LV dimensions, were
selected to test for a hypertrophic expression profile in the
knockdown cells (Carlson et al., 2013). Differential gene
expression analysis in knockdown experiments was performed
4
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RESULTS

using the R/Bioconductor package DESeq2 (Love et al., 2014).
Only genes with median depth of ≥10 reads were considered.
In particular, genes relevant to muscle contraction and regulation
were evaluated, including actin genes [actin alpha cardiac muscle
1 (ACTC1), actin alpha 1, skeletal muscle (ACTA1), actinin
alpha 1 (ACTN1)]; mammalian heart myosin heavy chain genes
[myosin heavy chain 6 (MYH6), myosin heavy chain 7 (MYH7)];
and the actin-binding protein gene transgelin (TAGLN; Warkman
et al., 2012; Despond and Dawson, 2018). A number of other
markers were also evaluated. Natriuretic peptide A (NPPA)
and natriuretic peptide B (NPPB) are evolutionarily conserved
genes expressed by the heart during the embryonic and fetal
stages. In adulthood, upon cardiac stress, NPPA and NPPB
are upregulated in the ventricular myocardium (Man et al.,
2018). Corin, serine peptidase (CORIN) is a cardiac serine
protease that acts as a pro-atrial natriuretic peptide convertase
(Wang et al., 2008). F-box protein 32 (encoded by FBXO32,
aliases MAFbx1, and ATROGIN1) is a cardiac and muscle
specific F-box protein with E3 ligase activity that localizes at
the sarcomere (Al-Yacoub et al., 2016). Tripartite motif containing
63 (TRIM63) encodes muscle RING finger 1, which maintains
muscle protein homeostasis by tagging the sarcomere proteins
with ubiquitin for subsequent degradation by the ubiquitinproteasome system and imparts loss-of-function effects on E3
ligase activity, which is causal for hypertrophy (Chen et al.,
2012). Programmed cell death 4 (PDCD4) is upregulated during
cardiomyocyte apoptosis and is involved in the inflammatory
response and cellular differentiation (Jia et al., 2016).

Study Population

Characteristics of the HyperGEN population are described in
Table 1, which compares participants above and below the
median value of LVM/Ht2.7 (note we dichotomized the phenotype
for this table only; discovery genetic models were of continuous
LV traits). On average, those with above-median LVM/Ht2.7
were older, more likely male, had higher BMI, and were more
likely to be diabetic. This group also had higher values of
other structural indices (RWT and LVIDD).

Single Variant Tests

There was no single variant with MAC > 5 that met the genomewide significance level threshold after correction for multiple
testing (p < 2.5 × 10−7) for the three echocardiographic traits.
Supplementary Figure S1 shows the QQ plots for single variant
analysis with (a) no variant filter, (b) MAC > 1 filter, and (c)
MAC > 5 filter. Three variants with MAC > 5 in three different
genes [regenerating family member 3 gamma (REG3G) for
lnRWT, activating transcription factor 7 interacting protein 2
(ATF7IP2) for lnLVIDD, and A-kinase anchoring protein 12
(AKAP12) for lnLVIDD] approached statistical significance
(Supplementary Table S2). As the majority of the borderline
significant SNP findings were very rare (MAC < 5), gene-based
results became the focus of the analysis and were used to select
genes to carry forward to functional cell-model assays.

Gene-Based Tests and Gene Prioritization

Ingenuity Pathway Analysis

Table 2 includes the gene-based results limited to the three genes
with the highest gene prioritization score (=5) selected for
knockdown in the hiPSC-CM model [myosin VIIA and Rab
interacting protein (MYRIP), trafficking protein particle complex
11 (TRAPPC11), and solute carrier family 27 member 6 (SLC27A6)].
Each gene was associated with a structural trait (lnLVIDD),
expressed in the hiPSC-CM model, and had SKAT-RC p < 1 × 10−4
for a total of three votes. Adjusting for BMI and, separately,
hypertension in the gene-based association test models did not

We used Ingenuity Pathway Analysis (IPA, QIAGEN, Inc.,
https://www.ingenuity.com) software to analyze the differential
mRNA expression gathered from the candidate gene knockdowns.
Pathway analysis uses observed expression changes and combines
these findings with predicted gene regulation and expression
changes in associated network genes and gives different
information than that provided by the knockdown models.
Due to our focus on echocardiographic traits, we selected
cardiovascular pathways to analyze in depth. We examined
IPA’s canonical cardiovascular signaling pathways including
cardiac hypertrophy signaling and cardiac beta-adrenergic
signaling. Additionally, we analyzed the pathway “Aldosterone
signaling in epithelial cells.” Aldosterone has been recognized
as being potentially hypertrophic (Yamamuro et al., 2006;
Messaoudi et al., 2013). We also analyzed the canonical toxicity
pathways for mitochondrial function and NRF2-mediated stress
responses. Finally, we looked at metabolism changes since a
switch from fatty acid (FA) metabolism to glucose metabolism
in cardiomyocytes can be indicative of cardiomyopathy (Pascual
and Coleman, 2016). This included IPA canonical pathways
for FA beta-oxidation and PPARA/RXRA activation. Pathways
could have either positive or negative z-scores for activation
or repression of pathways, respectively. The reported z-score
helps to infer the activation or repression of the implicated
biological functions based on the relationship between the
observed molecular network patterns and the derived effect
based on the literature.
Frontiers in Genetics | www.frontiersin.org

TABLE 1 | Descriptive characteristics of the Hypertension Genetic Epidemiology
Network (HyperGEN) African ancestry (AA) cohort.
N (%) or Below Median
Mean (SD)
LVM/Ht2
N
Age (years)
49.1 (11.2)
Female (%)
877 (64.3)
Field site
Alabama (%)
1,010 (74.0)
North Carolina (%)
315 (23.1)
Missing site data (%)
39 (2.9)
BMI (kg/m2)
32.0 (7.5)
Diabetes (%)
294 (21.6)
LVM/Ht2.7 (g/m2.7)
43.6 (12.6)
RWT
0.34 (0.05)
LVIDD (cm)
5.2 (0.5)

Above Median
LVM/Ht2

682
48.0 (11.3)
512 (75.1)

682
50.2 (11.1)
365 (53.5)

517 (75.8)
140 (20.5)
25 (3.7)
29.9 (6.4)
120 (17.6)
35.2 (7.0)
0.33 (0.05)
4.8 (0.3)

493 (72.3)
175 (25.7)
14 (2.0)
34.1 (7.9)
174 (25.5)
51.9 (11.4)
0.35 (0.06)
5.5 (0.5)

p

<0.001
<0.0001
0.037

<0.0001
<0.001
<0.0001
<0.0001
<0.0001

BMI, indicates body mass index; LVIDD, left ventricular internal dimension at diastole; LVM/
Ht2.7, left ventricular mass adjusted to height in meters2.7; and RWT, relative wall thickness.
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substantially change the results for the three genes. Each gene
received two additional votes corresponding to supportive
prioritization criteria. Single variant statistics for markers
contributing to gene-based tests, gene expression data from the
hiPSC-CM model, and fulfillment of gene prioritization categories
are presented in the Supplementary Spreadsheet. For MYRIP, the
two additional gene prioritization criteria were fulfilled by the
contribution of both rare and common variants to the gene-based
statistic (22 rare and two common) and that one of those variants
was a rare loss of function variant (3:40085643, MAF = 0.0004).
The average MAF of the 22 rare variants was 0.002 and the two
common variants (3:40223771 and 3:40275461) had MAF 0.23
and 0.10, respectively. SLC27A6 had 13 variants (average rare
variant MAF 0.006) contributing to the gene-based statistics, with
one variant being common (5:128301885, MAF = 0.21) fulfilling
one additional prioritization criteria. The other criterion was met
by an existing publication reporting a common (MAF = 0.37)
5’ UTR variant associated with LVH (Auinger et al., 2012). In
TRAPC11 both rare and common variants as well as a loss of
function variant were observed fulfilling two prioritization criteria.
The 22 rare variants had average MAF = 0.005, including the
loss of function variant (4:184633795) with MAF = 0.0004.

TRAPPC11 showed significant decreases in MYH7. MYRIP
knockdowns showed a very significant decrease in NPPA and
NPPB expression. TRAPPC11 knockdowns, however, showed
a significant increase in NPPB expression. PDCD4 was highly
upregulated in both SLC27A6 and MYRIP knockdowns.

Pathway Analysis of MYRIP Knockdowns

Differential expression analysis of MYRIP knockdowns compared
to the control identified changes in expression of cardiac
hypertrophy pathways. Both “Cardiac hypertrophy signaling”
and the “Role of NFAT (nuclear factor activated T cells) in
cardiac hypertrophy” pathways had significantly positive z-scores
greater than +1 (+2.4 and +3.1, respectively) suggesting pathway
activation (Figure 2) characterized by increased expression
of receptors, intermediate signalers, and downstream
hypertrophic effectors. The aldosterone-signaling pathway for
the MYRIP knockdown model was also scored as significantly
upregulated with a positive z-score of +2.3. Within this model
(Supplementary Figure S3), there is a significant increase
in expression of the aldosterone mineral corticoid receptor
nuclear receptor subfamily 3 group C member 2 (NR3C2).
Furthermore, within this pathway there is a significant increase
in the expression of protein kinase C epsilon (PRKCE) and
the Na+/H+ antiporter SLC9A1 when compared to control.
Differential expression pathway analysis showed a significant
decrease (z-score −5.2) in oxidative phosphorylation in MYRIP
knockdowns. Over 70% of genes involved in the canonical
oxidative phosphorylation pathway experienced a significant
decrease in expression compared to the control, while only
10% of genes were upregulated.

Candidate Gene hiPSC-CM Knockdowns

Each of the three prioritized genes was successfully knocked
down in the cell model using gene-specific siRNA. We used
RT-qPCR to show the efficiency of the knockdown procedures
(Supplementary Figure S2) before performing target whole
transcriptome sequencing. SLC27A6 proved the most efficient
knockdown at 96.5%, while TRAPPC11 and MYRIP each showed
significant expression reduction at 85.4 and 80.3%, respectively,
compared to control cells transfected with Silencer Negative
Control #3.

Pathway Analysis of SLC27A6
Knockdowns

Differential expression of SLC27A6 knockdowns predicted
significant upregulation of the “Cardiac hypertrophy signaling”
and “Role of NFAT in cardiac hypertrophy” pathways (zscores +1.9 and +1.7, respectively; see Figure 2). Aldosterone
signaling was also predicted to be upregulated (z-score +2.3)
due to the significantly increased expression of PKC genes
[like PRKCE and protein kinase D3 (PRKD3)] and mitogen

Cardiac Hypertrophy Markers

Expression profiling of hypertrophic gene markers in the
hiPSC-CM knockdowns overall suggest a decrease in hypertrophic
expression profiles (Figure 1). SLC27A6 and MYRIP knockdowns
both showed significant decrease in the expression of actin
genes ACTA1 and ACTC1. Knockdown of SLC27A6 and

TABLE 2 | Genes selected for functional follow up in human induced pluripotent stem cell cardiomyocyte (hiPSC-CM) models by prioritization scheme¶.
Trait

Gene

lnLVIDD
lnLVIDD
lnLVIDD

SLC27A6
TRAPPC11
MYRIP

Total Vars

Rare

13
22
24

10
17
21

Avg MAF
0.006
0.005
0.002

SKAT-RC* p

SKAT-RC§ p

SKAT-RC% p

3.37 × 10−6
4.71 × 10−5
3.93 × 10−5

2.58 × 10−7
4.15 × 10−4
2.86 × 10−5

8.10 × 10−6
4.07 × 10−5
8.11 × 10−6

SKAT-RMW† p
3.38 × 10−6
2.91 × 10−4
5.14 × 10−3

Avg MAF indicates average minor allele frequency; LVIDD, left-ventricular internal diastolic dimension; SKAT-RC, sequence kernel test-rare/common function; SKAT-RMW, sequence
kernel test-rare metal worker function; and Vars, variants. *Adjusted for age, sex, recruitment center, and 10 ancestry principal components (Pcs).
§
Additionally adjusted for body mass index.
%
Additionally adjusted for hypertension status.
†
Corrected for family relationships.
¶
Each gene was required to be associated with a structural trait [LVIDD, RWT, or left ventricular mass (LVM) adjusted to height in meters2.7] with p < 1 × 10−4, expressed in the hiPSCCM model, and broadly related to cardiovascular disease in the literature for a total of three points, additional points were accumulated for (1) Having a loss of function variant
[myosin VIIA and Rab interacting protein (MYRIP), trafficking protein particle complex 11 (TRAPPC11)], (2) Reference related to hypertrophy solute carrier family 27 member 6
(SLC27A6), (3) Having a mix of rare and common variants contribute to the gene-based statistic (MYRIP, SLC27A6, and TRAPPC11), or (4) Associated with more than one echo trait
with p < 0.05 (not observed for top genes) for a possible total of seven points.
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Pathway Analysis of TRAPPC11
Knockdowns

Comparison of TRAPPC11 knockdowns to the control showed
insignificant expression changes in canonical hypertrophic
pathways (Figure 2). Cardiac β-adrenergic signaling was predicted
to be downregulated with significant decrease in the expression
of Na+/Ca2+ exchanger member SLC8A1 and the ryanodine
receptor 2 (RYR2). Such a predicted decrease could lead to a
deficiency in Ca2+ handling (Supplementary Figure S5).
Furthermore, TRAPPC11 knockdowns showed more definitive
pathway changes for peroxisome proliferator-activated receptor
alpha/retinoid X receptor alpha (PPARA/RXRA) activation
compared to MYRIP and SLC27A6. RXRA and some other
downstream effectors had elevated expression leading to an
overall predicted upregulation of this pathway.

DISCUSSION
Increased left ventricular dimensions are prognostic of a host
of cardiovascular outcomes that overburden individuals of
African Ancestry. Among AAs, hypertension is associated with
abnormalities in left ventricular structure, including both
concentric (increased LVM with increased RWT and normal
or decreased LVIDD) and eccentric (increased LVM with
increased LVIDD) forms of hypertrophy (Abdalla et al., 2016).
Heritability studies (Sharma et al., 2006; Fox et al., 2010; Jin
et al., 2011) as well as prior genome-wide association
investigations (Arnett et al., 2009b, 2011; Vasan et al., 2009)
suggest genes contribute to variability in these phenotypes.
Previous studies have mostly focused on common genetic
variation and identified markers that explain only a small
portion of echocardiographic trait variation. We undertook a
whole-exome sequencing analysis of structural and functional
echocardiographic traits in the AA participants of the HyperGEN
study and used a data-driven gene prioritization procedure to
select genes for validation in a hiPSC-CM model. Three genes
were prioritized and successfully knocked down in the cells.
Compared to control cells, knockdown cells showed altered
expression of genes in cardiovascular pathways providing new
insight into disease-relevant mechanisms.
MYRIP is a Rab effector protein, which facilitates melanosome
transport and is detected in multiple tissues including the
heart. It is also is involved in secretory vesicle transport,
such as from the adrenal chromaffin cells (where catecholamines
such as epinephrine, norepinephrine, and dopamine are
produced and released systemically; Desnos et al., 2003). In
our study, MYRIP knockdown was associated with significantly
decreased expression of NPPA and NPPB, 2 adjacent and
highly conserved genes that have a complex relationship to
hypertrophic phenotypes. In our cell models, a decreased
expression appeared to be protective for LVH. However, in
the context of cardiac stress (e.g., cardiac ischemia), NPPA
and NPPB expression increases in response to pressure overloadinduced hypertrophy in a compensatory response (Man et al.,
2018). An inadequate response by these proteins may favor
natriuresis and ventricular dilation (i.e., increased LVIDD;

FIGURE 1 | Hypertrophic marker expression compared to control. Some
hypertrophic genes experienced significant changes in expression in the
knockdown model. False discovery rate (FDR), value of *p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001.

activated protein kinase phosphatase 1 (MPK1). Of particular
interest to the SLC27A6 knockdowns was the significant
upregulation among all genes associated to cholesterol
biosynthesis compared to the control. CAV3, which codes
for the caveolin protein in myocytes, was significantly
downregulated in the IPA pathway (Supplementary Figure S4)
and consistently we observed significantly decreased expression
of CAV3 in the SLC27A6 knockdown cardiomyocytes (value
of p 1.64 × 10−5), supporting a hypothesis of disrupted
caveolae formation (Figure 3).
Frontiers in Genetics | www.frontiersin.org
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FIGURE 2 | Changes in expression profiles of pathways relevant to cardiac hypertrophy in candidate gene knockdowns. Orange (diagonal stripes, checkerboard),
blue (dots, grid), and gray (triangles) colored boxes indicate significant changes in experimental pathway expression compared to the control ( p ≤ 0.05). Dark blue
(dots) indicates a significant negative z-score (≤−1) and a deactivation of the pathway, while dark orange (diagonal stripes) indicates a significant positive z-score (≥+1) and
activation. Light colored (checkerboard, grid) and gray boxes indicate insignificant z-scores. White boxes marked with an X had insignificant pathway expression
changes ( p ≥ 0.05).

Tamura et al., 2000; Man et al., 2018). MYRIP also significantly
changed expression of actins (ACTA1 and ACTC1) and
TAGLN, myocyte structural proteins. Variants in ACTC1
have been associated with idiopathic dilated cardiomyopathy
and familial hypertrophic cardiomyopathy (Augiere et al.,
2015; Frustaci et al., 2018). Differential expression analysis
of MYRIP knockdowns compared to the control in IPA also
showed changes in aldosterone signaling that included an
increase in expression of the aldosterone mineral corticoid
receptor, NR3C2. The mineral corticoid receptor is widely
expressed in the cardiovascular system and is a major
determinant of endothelial function, smooth muscle tone,
vascular remodeling, and hypertension (Belden et al., 2017).
Individuals of AA are particularly prone to hypertension
associated with primary aldosteronism (Zilbermint et al.,
2019). A potential upregulation of this pathway further
validates a role of MYRIP in left ventricular remodeling.
Finally, based on gene expression, there was a very significant
predicted decrease in the regulation of the oxidative
phosphorylation pathway in MYRIP knockdowns, suggesting
a state of relative energy deprivation characteristic of LVH
and heart failure (Scolletta and Biagioli, 2010).
SLC27A6 encodes a member of the FA transport protein family
(FATP6), the predominant FA transporter in the heart. In the
healthy heart, ATP requirements are generally met by FA oxidation
with smaller contributions from other sources (such as glucose,
lactate, and branch-chain amino acids); increased reliance on
non-FA fuels is characteristic of a “fetal program” of substrate
metabolism typical of LVH (Neubauer, 2007; Tuunanen et al.,
2008). SLC27A6 has also been linked to other CV-related outcomes
in humans (Nielsen et al., 2018; Roselli et al., 2018; Van Der
Harst and Verweij, 2018). With the knockdown of SLC27A6, IPA
also predicted decreased expression of caveolin 3 (CAV3). This
relationship was confirmed in our cell model. Caveolae are
cholesterol- and sphingolipid-enriched membrane microdomains
that contain caveolins, structural proteins that are involved in
cell growth and hypertrophy by organizing receptors and signaling

Frontiers in Genetics | www.frontiersin.org

FIGURE 3 | SLC27A6 knockdowns show a decreased expression of
caveolin 3 (CAV3) compared to the control. A significant decrease in CAV3
expression was noted in the SLC27A6 knockdowns. ****FDR p < 0.0001.

molecules (including G-protein coupled receptors and natriuretic
peptide receptors; Horikawa et al., 2011). There are three caveolin
isoforms, and previous research has shown Cav3 knockout mice
show signs of muscle myopathic changes, cardiac hypertrophy,
and cardiomyopathy (Woodman et al., 2002). Upregulation of
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Cav3 in a neonatal cardiac myocyte model reduced the ability
of an adrenergic agonist (i.e., phenylephrine) and endothelin-1
to provoke hypertrophy in that model (Koga et al., 2003). Another
study showed that transgenic mice with cardiac myocyte-specific
overexpression of Cav3 that were subjected to transverse aortic
constriction had increased survival, reduced cardiac hypertrophy,
and maintenance of cardiac function compared with control mice.
Mutations in Cav3 have also been linked to the long QT type
9 inherited arrhythmia syndrome (Tyan et al., 2019). As predicted
by IPA as a consequence of SLC27A6 downregulation was SLC27A1
(alias FATP1) upregulation, which may be compensatory. In the
heart, overexpression of SLC27A1 leads to LVH and LV diastolic
dysfunction similar to that seen with diabetic cardiomyopathy (a
consequence of high circulating FAs and the insulin-resistant heart
unable to bring in glucose; Chiu et al., 2005; Wu et al., 2006).
Overall, a downregulation of SLC27A6 may lead to downregulation
of CAV3 and upregulation of SLC27A1, which is plausibly involved
in ventricular remodeling. PDCD4, which was upregulated in the
SLC27A6 knockdown, may be another signal of increased cardiac
apoptosis that is associated with cardiac stress, resulting in an
increase in LVIDD (i.e., eccentric LVH; Xiao et al., 2016).
Transport protein particles (TRAPP) are parts of a multiprotein
complex involved in endoplasmic reticulum-to-Golgi trafficking
(Sacher et al., 1998; Kim et al., 2006; Scrivens et al., 2011).
It is ubiquitously expressed in humans, reflecting its important
role in basic cellular functions. The TRAPPC11 protein
participates in numerous interactions with other TRAPP complex
components. Similar to SLC27A6, TRAPC11 knockdown was
associated with fewer alterations in hypertrophic marker
expression as compared to MYRIP. In IPA, a decrease in cardiac
β-adrenergic signaling was linked to a decrease in the expression
of the Na+/Ca2+ exchanger and RYR2, potentially leading to a
deficiency in Ca2+ handling. Overall, a downregulation TRAPPC11
supports a defect in the transport of secretory proteins, potentially
involving Ca2+ that warrants further investigation.
This study leverages several strengths, including a wholeexome association discovery analysis of echocardiographic traits
in a population of well-characterized participants of AA. We used
a combination of statistical analysis, publicly available
bioinformatics data, and gene expression data from our control
cell models to prioritize our top findings. This resulted in a
novel list of genes for functional follow-up in hiPSC-CMs.
Limitations included the inability to test specific variants or
groups of variants identified in human exomes in the cell model,
where instead we used whole-gene siRNA knockdown as a proxy
for gene disruption due to identified variants. Additionally, human
induced pluripotent stem cell derived cardiomyocytes are known
to not fully replicate the maturity of human cardiac myocytes.
However, in this study, we used the commercially available iCell
cardiomyocytes for the knockdown experiments, which were
developed to represent a highly pure population of cardiomyocytes.
Prior research performed a detailed quantitative analysis of the
electrophysiological properties of these cells demonstrating several
properties characteristic of mature cardiac myocytes (Ma et al.,
2011). Further, the genes were not replicated in an independent
population due to the difficulty finding comparable whole exome
data paired with echocardiography in AAs. Also, these findings
Frontiers in Genetics | www.frontiersin.org

represent genes discovered in a relatively healthy population
and validated in a model of normal cardiomyocytes. Future
studies are needed to determine a role for these genes in diseased
individuals and cell models (or even additional in vivo models).
The current study discovered three novel candidates (MYRIP,
SLC27A6, and TRAPPC11) associated with LV internal diastolic
dimension in AAs from HyperGEN. The three genes were
successfully knocked down in a hiPSC-CM model and markers
of hypertrophy were compared between the knockdown and
controls cells. Knockdown of each gene was associated with
significant cellular changes that give new insight into left-ventricular
remodeling. In particular, MYRIP was associated with cardiac
hypertrophy signaling (e.g., NFAT pathway, NPPA, and NPPB)
and aldosterone signaling. SLC27A6 is a fatty acid transporter
and our knockdown of the gene led to changes in caveolin
expression (CAV3) whose protein product has previously been
linked to hypertrophic phenotypes in animal models. Finally,
TRAPPC11 was linked to a deficiency in calcium handling and
RYR2 expression. In summary, the three genes are biologically
plausible candidates associated with left ventricular structure and
metabolism according to the results of the knockdown experiments.
Future functional studies that focus on specific variants under
normal and stress conditions in the hiPSC-CM models are warranted.
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GLOSSARY
Term

Definition

AA

African ancestry

AAs
BMI
CV
CVD
FA
GATK®
GVCF
hiPSC-CM
HyperGEN
iCell-CMs
INDEL
IPA
IVS
LV
LVH
LVIDD
LVM
LVM/Ht2.7
MAC
MAF
NFAT
PC
PWT
QC
RMW
RT-qPCR
RWT
siRNA
SKAT-RC
SKAT
SNP

participants of African ancestry
body mass index
cardiovascular
cardiovascular disease
fatty acid
Genome Analysis ToolKit
genomic variant call format
human induced pluripotent stem cell cardiomyocyte
the Hypertension Genetic Epidemiology Network (study)
iCell® Cardiomyocytes
insertion-deletion genetic variant
Ingenuity Pathway Analysis
interventricular septum thickness
left ventricular
left ventricular hypertrophy
left ventricular internal diastolic dimension
left ventricular mass
left ventricular mass adjusted to height2.7
minor allele count,
minor allele frequency
nuclear factor activated T cells
principal component
posterior wall thickness at end-diastole
quality control
RAREMETALWORKER (analysis tool)
real-time quantitative polymerase chain reaction
relative wall thickness
small interfering RNA
rare/common function in sequence kernel asssociation test
Sequence Kernel Asssociation Test (analysis tool)
single-nucleotide polymorphism
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